Revelation Biosciences
REVB
5 hedge funds and large institutions have $467K invested in Revelation Biosciences in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
17% less funds holding
Funds holding: 6 → 5 (-1)
29% less capital invested
Capital invested by funds: $656K → $467K (-$189K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$14.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$21.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.56K |
REVB Hedge Fund Activity: Q4 2023 in Review
5 of the 6,862 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q4 2023, worth a combined $467K — down 29% from $656K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of REVB and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Walleye Capital, adding an estimated $14.3K. The largest seller was Citadel Advisors, cutting an estimated $21.4K.
- 5 institutional investors held Revelation Biosciences (REVB) as of Q4 2023, down from 6 in Q3 2023.
- Funds reported $467K of Revelation Biosciences stock for Q4 2023, down 29% quarter-over-quarter.
- 0 funds opened new Revelation Biosciences positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest Revelation Biosciences buyer in Q4 2023 was Walleye Capital, an estimated $14.3K added.
- The largest Revelation Biosciences seller in Q4 2023 was Citadel Advisors, an estimated $21.4K sold.
Based on aggregated 13F filings for Q4 2023.